Concomitant endothelin receptor subtype-A blockade during the progression of pacing-induced congestive heart failure in rabbits: Beneficial effects on left ventricular and myocyte function

Circulation

Volumn 95, Issue 7, 1997, Pages 1918-1929

  Spinale, Francis G ^a   Walker, Jennifer D ^c   Mukherjee, Rupak ^c   Iannini, Julie P ^c   Keever, Anthony T ^c   Gallagher, Kim P ^a,b  

^a MEDICAL UNIVERSITY OF SOUTH CAROLINA   (United States)

^b PFIZER INC   (United States)

^c NONE

Author keywords

contractility; endothelin; heart failure; receptor; ventricles

Indexed keywords

4 (4 METHOXYPHENYL) 2 (3,4 METHYLENEDIOXYPHENYL) 4 OXO 3 (3,4,5 TRIMETHOXYBENZYL) 2 BUTENOIC ACID; CALCIUM ION; ENDOTHELIN; ENDOTHELIN 1; ENDOTHELIN A RECEPTOR; ENDOTHELIN A RECEPTOR ANTAGONIST; NORADRENALIN;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CONGESTIVE HEART FAILURE; CONTROLLED STUDY; DRUG BLOOD LEVEL; HEART CONTRACTION; HEART LEFT VENTRICLE CONTRACTION; HEART LEFT VENTRICLE ENDDIASTOLIC VOLUME; HEART LEFT VENTRICLE FUNCTION; HEART MUSCLE CELL; HEART VENTRICLE PACING; HEMODYNAMICS; INOTROPISM; NONHUMAN; NORADRENALIN BLOOD LEVEL; PRIORITY JOURNAL; RABBIT; RECEPTOR BLOCKING; SUBCUTANEOUS DRUG ADMINISTRATION;

EID: 0030999847     PISSN: 00097322     EISSN: None     Source Type: Journal    
DOI: 10.1161/01.CIR.95.7.1918     Document Type: Article

References (61)

1. Kramer BK, Nishida M, Kelly RA, Smith TW. Endothelins: myocardial actions of a new class of cytokines. Circulation. 1992;85: 350-356.
2. Hirata K, Matsuda Y, Akita H, Yokoyama M, Fukuzaki H. Myocardial ischemia induced by endothelin in the intact rabbit: angiographic analysis. Cardiovasc Res. 1990;24:879-883.
3. Lerman A, Hildebrand FL Jr, Aarhus LL, Burnett JC Jr. Endothelin has biological actions at pathophysiological concentrations. Circulation. 1991;83:1808-1814.
4. Cannan CR, Burnett JC Jr, Lerman A. Enhanced coronary vasoconstriction to endothelin-B receptor activation in experimental congestive heart failure. Circulation. 1996;93:646-651.
5. Gray GA. Pharmacological characterization of endothelin receptors. In: Gray GA, Webb DJ. Molecular Biology and Pharmacology of the Endothelins. Austin, Tex: RG Landes Co; 1995:61-94.
6. Sokolovsky M. Structure-function relationships of endothelins, sarafotoxins, and their receptor subtypes. J Neurochem. 1992;59: 809-821.
7. Yanagisawa M, Kurihara H, Kimura S, Tomobe Y, Kobayashi M, Mitsui Y, Yazaki Y, Goto K, Masaki T. A novel potent vasoconstrictor peptide produced by vascular endothelial cells. Nature. 1988;332:411-415.
8. Tonnessen T, Giaid A, Saleh D, Naess PA, Yanagisawa M, Christensen G. Increased in vivo expression and production of endothelin-1 by porcine cardiomyocytes subjected to ischemia. Circ Res. 1995;76:767-772.
9. Shichiri M, Hirata Y, Nakajima T, Ando K, Imai T, Yanagisawa M, Masaki T, Marumo F. Endothelin-1 is an autocrine/paracrine growth factor for human cancer cell lines. J Clin Invest. 1991;87: 1867-1871.
10. Thomas PB, Liu ECK, Webb ML, Mukherjee R, Spinale FG. Evidence of the endothelin-1 autocrine loop in cardiac myocytes: relation to contractile function with congestive heart failure. Am J Physiol. 1996;40:H2629-H2673.
11. Wei CM, Lerman A, Rodeheffer RJ, McGregor CGA, Brandt RR, Wright S, Heublein DM, Kao PC, Edwards WD, Burnett JC Jr. Endothelin in human congestive heart failure. Circulation. 1994;89: 1580-1586.
12. Cody RJ, Haas GJ, Binkley PF, Capers Q, Kelley R. Plasma endothelin correlates with the extent of pulmonary hypertension in patients with chronic congestive heart failure. Circulation. 1992;85: 504-509.
13. Tsutamoto T, Wada A, Maeda Y, Adachi T, Kinoshita M. Relation between endothelin-1 spillover in the lungs and pulmonary vascular resistance in patients with chronic heart failure. J Am Coll Cardiol. 1994;23:1427-1433.
14. Margulies KB, Hildebrand FL Jr, Lerman A, Perrella MA, Burnett JC Jr. Increased endothelin in experimental heart failure. Circulation. 1990;82:2226-2230.
15. Nootens M, Kaufmann I, Rector T, Toher C, Judd D, Francis GS, Rich S. Neurohormonal activation in patients with right ventricular failure from pulmonary hypertension: relation to hemodynamic variables and endothelin levels. J Am Coll Cardiol. 1995;26: 1581-1585.
16. Jones LG, Rozich JD, Tsutsui H, Cooper G. Endothelin stimulates multiple responses in isolated adult ventricular cardiac myocytes. Am J Physiol. 1992;263:H1447-H1454.
17. Takanashi M, Endoh M. Concentration and time-dependence of phosphoinositide hydrolysis induced by endothelin-1 in relation to the positive inotropic effect in the rabbit ventricular myocardium. J Pharmacol Exp Ther. 1992;262:1189-1194.
18. Masaki T, Kimura S, Yanagisawa M, Goto K. Molecular and cellular mechanism of endothelin regulation: implications for vascular function. Circulation. 1991;84:1457-1468.
19. Ono K, Tsujimoto G, Sakamoto A, Eto K, Masaki T, Ozaki Y, Satake M. Endothelin-A receptor mediates cardiac inhibition by regulating calcium and potassium currents. Nature. 1994;370: 301-304.
20. 2+ current by a G protein-dependent mechanism in rabbit cardiac myoctyes. J Physiol. 1992;448:729-747.
21. Watanabe T, Kusumoto K, Kitayoshi T, Shimamoto N. Positive inotropic and vasoconstrictive effects of endothelin-1 in in vivo and in vitro experiments: characteristics and the role of the L-type calcium channel. J Cardiovasc Pharmacol. 1989;13:S106-S111.
22. Kelly RA, Eid H, Kramer BK, ONeill M, Liang BT, Reers M, Smith TW. Endothelin enhances the contractile responsiveness of adult rat ventricular myocytes to calcium by a pertussis toxin-sensitive pathway. J Clin Invest. 1990;86:1164-1171.
23. Sokolovsky M. Functional coupling between endothelin receptors and multiple G-proteins in rat heart myocytes. Receptors Channels. 1993;1:295-304.
24. James AF, Xie LH, Fujitani Y, Hayashi S, Horie M. Inhibition of the cardiac protein kinase A-dependent chloride conductance by endothelin-1. Nature. 1994;370:297-300.
25. + exchanger. Circ Res. 1991;68:269-279.
26. McClellan G, Weisberg A, Winegrad S. Effect of endothelin-1 on actomyosin ATPase activity: implications for the efficiency of contraction. Circ Res. 1996;78:1044-1050.
27. Sakai S, Miyauchi T, Sakurai T, Kasuya Y, Ihara M, Yamaguchi I, Goto K, Sugishita Y. Endogenous endothelin-1 participates in the maintenance of cardiac function in rats with congestive heart failure. Circulation. 1996;93:1214-1222.
28. Molenaar P, O'Reilly G, Sharkey A, Kuc RE, Harding DP, Plumpton C, Gresham GA, Davenport AP. Characterization and localization of endothelin receptor subtypes in human atrioventricular conducting system and myocardium. Circ Res. 1993;72: 526-538.
29. Ito H, Hirata Y, Hiroe M, Tsujino M, Adachi S, Takamoto T, Nitta M, Taniguchi K, Marumo F. Endothelin-1 induces hypertrophy with enhanced expression of muscle-specific genes in cultured neonatal rat cardiomyocytes. Circ Res. 1991;69:209-215.
30. Teerlink JR, Loffler BM, Hess P, Maire JP, Clozel M, Clozel JP. Role of endothelin in the maintenance of blood pressure in conscious rats with chronic heart failure: acute effects of the endothelin receptor antagonist Ro 47-0203 (Bosentan). Circulation. 1994;90: 2510-2518.
31. Ihara M, Ishikawa K, Fukuroda T, Saeki T, Funabashi K, Fukami T, Suda H, Yano M. In vitro biological profile of a highly potent novel endothelin (ET) antagonist BQ-123 selective for the ETA receptor. J Cardiovasc Pharmacol. 1992;20:S11-S14.
32. Reynolds EE, Keiser JA, Haleen SJ, Walker DM, Olszewski B, Schroeder RL, Taylor DG, Hwang OK, Welch KM, Flynn MA, Thompson DM, Edmunds JJ, Berryman KA, Plummer M, Cheng XM, Patt WC, Doherty AM. Pharmacological characterization of PD 156707, an orally active ETA receptor antagonist. J Pharmacol Exp Ther. 1995;273:1410-1417.
33. Doherty AM, Patt WC, Edmunds JJ, Berryman KA, Reisdorph BR, Plummer MS, Shahripour A, Lee C, Cheng XM, Walker DM, Haleen SJ, Keiser JA, Flynn MA, Welch KM, Hallak H, Taylor DG, Reynolds EE. Discovery of a novel series of orally active non-peptide endothelin-A (ETA) receptor-selective antagonists. J Med Chem. 1995;38:1259-1263.
34. Spinale FG, Zellner JL, Tomita M, Crawford FA, Zile MR. Relationship between ventricular and myocyte remodeling with the development and regression of supraventricular tachycardia-induced cardiomyopathy. Circ Res. 1991;69:1058-1067.
35. Spinale FG, Tanaka R, Crawford FA, Zile MR. Changes in myocardial blood flow during the development of and recovery from tachycardia-induced cardiomyopathy. Circulation. 1992;85:717-729.
36. Wang J, Seyedi N, Xu XB, Wolin MS, Hintze TH. Defective endothelium-mediated control of coronary circulation in conscious dogs after heart failure. Am J Physiol. 1994;266:H670-H680.
37. Travill CM, Williams TDM, Pate P, Song G, Chalmers J, Lightman SL, Sutton R, Noble MIM. Haemodynamic and neurohumoral response in heart failure produced by rapid ventricular pacing. Cardiovasc Res. 1992;26:783-790.
38. Spinale FG, Fullbright BM, Mukherjee R, Tanaka R, Hu J, Crawford FA, Zile MR. Relation between ventricular and myocyte function with tachycardia-induced cardiomyopathy. Circ Res. 1992; 71:174-187.
39. Roth DA, Urasawa K, Helmer GA, Hammond HK. Downregulation of cardiac guanosine 5′-triphosphate-binding proteins in right atrium and left ventricle in pacing-induced congestive heart failure. J Clin Invest. 1993;91:939-949.
40. Spinale FG, Holzgrefe HH, Mukherjee R, Hird RB, Walker JD, Arnim-Barker A, Powell JR, Koster WH. Angiotensin-converting enzyme inhibition and the progression of congestive cardiomyopathy: effects on left ventricular and myocyte structure and function. Circulation. 1995;92:562-578.
41. Spinale FG, Temple GE, Mukherjee R, Eble DM, Brown R, Vacchiano CA, Zile MR. Cellular and molecular alterations in the β-adrenergic system with cardiomyopathy induced by tachycardia. Cardiovasc Res. 1994;28:1243-1250.
42. Calderone A, Rouleau JL, deChamplain J, Belichard P, Stewart DJ. Regulation of the endothelin-1 transmembrane signaling pathway: the potential role of agonist-induced desensitization in the coronary artery of the rapid ventricular pacing-overdrive dog model of heart failure. J Mol Cell Cardiol. 1993;25:895-903.
43. Freeman GL, Colston JT. Myocardial depression produced by sustained tachycardia in rabbits. Am J Physiol. 1992;262:H63-H67.
44. Spinale FG, Eble DM, Mukhetjee R, Johnson WS, Walker JD. Left ventricular and myocyte structure and function following chronic ventricular tachycardia in rabbits. Basic Res Cardiol. 1994;89: 456-467.
45. Zile MR, Mukherjee R, Clayton C, Kato S, Spinale FG. Effects of chronic supraventricular pacing tachycardia on relaxation rate in isolated cardiac muscle cells. Am J Physiol. 1995;268:H2104-2113.
46. Mukherjee R, Hewett KW, Spinale FG. Myocyte electrophysiological properties following the development of supraventricular tachycardia induced cardiomyopathy. J Mol Cell Cardiol. 1995;27: 1333-1348.
47. +2-pump ATPase activity in tachycardia heart failure. Cell Calcium. 1994;16:349-356.
48. Perreault CL, Shannon RP, Komamura K, Vatner SF, Morgan JP. Abnormalities in intracellular calcium regulation and contractile function in myocardium from dogs with pacing-induced heart failure. J Clin Invest. 1992;89:932-938.
49. 1-receptor downregulation in heart failure. Circ Res. 1986;59:297-309.
50. Benedict CR, Weiner DH, Johnstone DE, Bourassa MG, Ghali JK, Nicklas J, Kirlin P, Greenberg B, Quinones MA, Yusuf S. Comparative neurohormonal responses in patients with preserved and impaired left ventricular ejection fraction: results of the Studies of Left Ventricular Dysfunction (SOLVD) Registry. J Am Coll Cardiol. 1993;22:146A-153A.
51. Kiowski W, Sutsch G, Hunziker P, Muller P, Kim J, Oechslin E, Schmitt R, Jones R, Bertel O. Evidence for endothelin-1-mediated vasoconstriction in severe chronic heart failure. Lancet. 1995;346: 732-736.
52. Neglia D, Parodi O, Gallopin M, Sambuceti G, Giorgetti A, Pratali L, Salvadori P, Michelassi C, Lunardi M, Pelosi G, Marzilli M, L'Abbate A. Myocardial blood flow response to pacing tachycardia and to dipyridamole infusion in patients with dilated cardiomyopathy without overt heart failure: a quantitative assessment by positron emission tomography. Circulation. 1995;92:796-804.
53. B receptors mediate contraction to endothelin-1 in human blood vessels. Circulation. 1994;89:1203-1208.
54. Weber KT, Anversa P, Armstrong PW, Brilla CG, Burnett JC Jr, Cruickshank JM, Devereux RB, Giles TD, Korsgaard N, Leier CV, Mendelsohn FAO, Motz WH, Mulvany MJ, Strauer BE. Remodeling and reparation of the cardiovascular system. J Am Coll Cardiol. 1992;20:3-16.
55. Ebhbali-Webb M. Cardiac fibroblasts. In: Eghbali-Webb M, ed. Molecular Biology of the Collagen Matrix in the Heart. Austin, Tex: RG Landes Co; 1995:24-40.
56. +2 modulation. Circ Res. 1996;78:302-311.
57. Roubert P, Gillard V, Plas P, Guillon JM, Chabrier PE, Braquet P. Angiotensin II and phorbol esters potently down regulate endothelin (ET-1) binding sites in vascular smooth muscle cells. Biochem Biophys Res Commun. 1989;164:809-815.
58. Miyauchi T, Yanagisawa M, Tomizawa T, Sugishita Y, Suzuki N, Fujino M, Ajisaka R, Goto K, Masaki T. Increased plasma concentrations of endothelin-1 and big endothelin-1 in acute myocardial infarction. Lancet. 1989;2:53-54.
59. Morkin E, Kimata S, Skillman JJ. Myosin synthesis and degradation during development of cardiac hypertrophy in the rabbit. Circ Res. 1972;30:690-702.
60. Gross DR. Animal Models in Cardiovascular Research. Dordrecht, Netherlands: Kluwer Academic Publishers; 1994:373-376.
61. B contractile receptors. Eur J Pharmacol. 1994;257:307-310.